Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 195

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Prognostic effects of TERT promoter mutations are enhanced by coexistence with BRAF or RAS mutations and strengthen the risk prediction by the ATA or TNM staging system in differentiated thyroid cancer patients

Open access
Song, Young Shin, Lim, Jung Ah, Choi, Hoonsung, Won, Jae‐Kyung, Moon, Jae Hoon, Cho, Sun Wook, Lee, Kyu Eun, Park, Young Joo, Yi, Ka Hee, Park, Do Joon, Seo, Jeong‐Sun · 2016 · Cancer

Abstract

BACKGROUND: Recent reports suggest that mutations in the promoter of the gene encoding telomerase reverse transcriptase (TERT) affect thyroid cancer outcomes. METHODS: In all, 551 patients with differentiated thyroid cancer (DTC) enrolled in this study. The median follow‐up duration was 4.8 years (interquartile range, 3.4‐10.6 years). RESULTS: TERT promoter mutations were detected in 25 DTCs (4.5%): 2.8% in neither BRAF‐mutated nor RAS‐mutated tumors, 4.8% in BRAF‐mutated tumors, and 11.3% in RAS‐mutated tumors. Moreover, they were frequently observed in American Thyroid Association (ATA) high‐risk and TNM stage III/IV groups (9.1% and 12.9%, respectively). The coexistence of BRAF or RAS with TERT promoter mutations increased aggressive clinicopathologic features, recurrence (hazard ratio [HR] for BRAF, 4.64; 95% confidence interval [CI], 1.42‐15.18; HR for RAS, 5.36; 95% CI, 1.20‐24.02), and mortality (HR for BRAF, 15.13; 95% CI, 1.55‐148.23; HR for RAS, 14.75; 95% CI, 1.30‐167.00), even after adjustments for the age at diagnosis and sex, although the significance was lost after additional adjustments for pathologic characteristics. Furthermore, TERT promoter mutations significantly increased the risk of both recurrence and mortality in the ATA high‐risk (HR for recurrence, 5.79; 95% CI, 2.07‐16.18; HR for mortality, 16.16; 95% CI, 2.10‐124.15) and TNM stage III/IV groups (HR for recurrence, 3.60; 95% CI, 1.19‐10.85; HR for mortality, 9.06; 95% CI, 2.09‐39.26). CONCLUSIONS: The coexistence of BRAF or RAS mutations enhanced the prognostic effects of TERT promoter mutations. Furthermore, TERT promoter mutations strengthened the predictions of mortality and recurrence by the ATA and TNM staging systems, particularly for high‐risk patients with DTC. Cancer 2016;122:1370–1379. © 2016 American Cancer Society.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/cncr.29934

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

Metadata

Authors
Song, Y. S., Lim, J. A., Choi, H., Won, J., Moon, J. H., Cho, S. W., Lee, K. E., Park, Y. J., Yi, K. H., Park, D. J., & Seo, J.
Venue
Cancer
Publisher
Wiley
Published
2016-03-11
Volume
122
Issue
9
Pages
1370-1379
ISSN
  • 0008-543X (ISSN-L)
  • 1097-0142
OpenAlex
W2296729886
Cited by
195
References
2
FWCI
23.09
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.